Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03738098 · ClinicalTrials.gov registry record · NA
NYCKidSeq: Incorporating Genomics Into Clinical Care of Diverse NYC Children
A NA study of Genetic Predisposition to Disease and Genetic Diseases, Inborn, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- NA
- Development phase
- 650
- Enrollment target
- 2
- Study locations
NCT03738098: Completed NA study of Genetic Predisposition to Disease and Genetic Diseases, Inborn, sponsored by Icahn School of Medicine at Mount Sinai.
NCT03738098 is a NA study of Genetic Predisposition to Disease and Genetic Diseases, Inborn that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 650 participants, below the 182,465-participant average among 11 other Genetic Predisposition to Disease trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03738098, a NA study of Genetic Predisposition to Disease and Genetic Diseases, Inborn, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- NA
- Development phase
- 650 participants
- Enrollment target
- 2
- Study locations
Study Summary
The NYCKidSeq program will significantly advance the implementation of genomic medicine, particularly for children, young adults and their families in Harlem and the Bronx. The study will assess the clinical utility of genomic medicine in three broad areas of pediatric disorders, while engaging a range of providers and community advisors to overcome the well-documented barriers to inclusion of underserved and underrepresented populations in genomic research. The study will also include testing, analyzing, and implementing a novel communication tool, Genomic Understanding, Information and Awareness (GUÍA), to facilitate the return of genomic test results. The use of GUÍA will enhance the understanding of these genomic testing results by families, patients, and care providers at all levels of expertise, in two health systems. Healthcare system leadership will be engaged to provide insights into their readiness for genomic implementation. Overall, the NYCKidSeq program will inform the genomics and clinical communities about how to implement genomic medicine in a diverse population in a clinically useful, technologically savvy, culturally sensitive, and ethically sound manner.
Primary Outcome
Perceived understanding of genomic testing results. Scale from 1 (very little or none of it) to 5 (understood almost all or all of it) at 3 months
Conditions Studied
Interventions
- BEHAVIORAL Standard of Care
- BEHAVIORAL GUÍA
Study Locations (2)
New York
- Icahn School of Medicine at Mount Sinai - New York
- Albert Einstein College of Medicine/Montefiore - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2019-01-30 |
| Est. Completion | 2022-04-28 |
| Phase | NA |
What the finished NCT03738098 record still lists
NCT03738098 is an interventional study that assigns participants to a tested intervention. The registered 650 participants enrollment target is mid-sized for trials with a published cap, below the 182,465-participant average among 11 other Genetic Predisposition to Disease trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Genetic Predisposition to Disease appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT03738098 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03738098 about?
NCT03738098 is a clinical study titled "NYCKidSeq: Incorporating Genomics Into Clinical Care of Diverse NYC Children". The NYCKidSeq program will significantly advance the implementation of genomic medicine, particularly for children, young adults and their families in Harlem and the Bronx. The study will assess the clinical utility of genomic medicine in three broad areas of pediatric disorders, while engaging a ra...
What is the current status of trial NCT03738098?
This trial is currently completed. It is a NA study. The enrollment target is 650 participants. The study started on 2019-01-30. Estimated completion is 2022-04-28.
What conditions does trial NCT03738098 study?
This clinical trial studies the following conditions: Genetic Predisposition to Disease, Genetic Diseases, Inborn.
What interventions are being tested in trial NCT03738098?
The interventions under investigation include: Standard of Care (BEHAVIORAL), GUÍA (BEHAVIORAL).
Who is sponsoring clinical trial NCT03738098?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03738098 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Predisposition to Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03738098's enrollment target sits among peer trials
650 5th of 11 higher than 7 of 11 other Genetic Predisposition to Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Genetic Predisposition to Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing
RECRUITING · NA
-
VIGOR: Virtual Genome Center for Infant Health
RECRUITING
-
Identification of Genomic Predictors of Adverse Events After Cardiac Surgery
RECRUITING
-
Blood Markers of Early Pancreas Cancer
RECRUITING
-
Microbiome and Association With Implant Infections
RECRUITING · Phase 2
-
Helix Research Network
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02934477 · 650 participants
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- NCT04579120 · 650 participants
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- NCT04875702 · 650 participants · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
- NCT05046600 · 650 participants
Registry of Arthrex Hand and Wrist Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI